Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

6,179JPY
21 Nov 2017
Change (% chg)

¥-10 (-0.16%)
Prev Close
¥6,189
Open
¥6,209
Day's High
¥6,247
Day's Low
¥6,174
Volume
1,719,000
Avg. Vol
2,056,893
52-wk High
¥6,464
52-wk Low
¥4,555

Chart for

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.71
Market Cap(Mil.): ¥4,891,410.00
Shares Outstanding(Mil.): 790.85
Dividend: 90.00
Yield (%): 2.91

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

BRIEF-U.S. FDA provides new drug safety communication on Takeda's gout drug

* U.S. FDA says preliminary results from a safety clinical trial show increased risk of heart-related death with Febuxostat (Uloric) versus Allopurinol

15 Nov 2017

BRIEF-TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

* TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

14 Nov 2017

Takeda takes on Sanofi with new global dengue vaccine data

Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia.

06 Nov 2017

Takeda takes on Sanofi with new global dengue vaccine data

Nov 7 Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia.

06 Nov 2017

BRIEF-Takeda and HemoShear Therapeutics enter drug discovery partnership in liver diseases

* Takeda and HemoShear Therapeutics enter into exclusive drug discovery partnership in liver diseases

17 Oct 2017

BRIEF-Takeda gets FDA approval for ALUNBRIG 180 mg tablets

* Takeda announces FDA approval of ALUNBRIG (brigatinib) 180 mg tablets

03 Oct 2017

BRIEF-Takeda, SGC in collaboration agreement related to inflammatory bowel disease

* Takeda and SGC announce a collaboration agreement using patient tissue-based assays for clinical target validation in inflammatory bowel disease

28 Sep 2017

Fujifilm says aims to spend $4.5 billion on M&A over three years

TOKYO Fujifilm Holdings Corp said it aimed to spend 500 billion yen ($4.54 billion) in strategic acquisitions over three years as it seeks growth outside its traditional photographic film business, which has been shrinking.

30 Aug 2017

Fujifilm says aims to spend $4.5 billin on M&A over three years

TOKYO Fujifilm Holdings Corp said it aimed to spend 500 billion yen ($4.54 billion) in strategic acquisitions over three years as it seeks growth outside its traditional photographic film business, which has been shrinking.

30 Aug 2017

Fujifilm says aims to spend $4.5 bln on M&A over 3 years

TOKYO, Aug 30 Fujifilm Holdings Corp said it aimed to spend 500 billion yen ($4.54 billion) in strategic acquisitions over three years as it seeks growth outside its traditional photographic film business, which has been shrinking.

30 Aug 2017

Earnings vs. Estimates